NeuroCME
EXPERT VIDEOCME

Pressing Issues in Progressive MS: Experts Convene

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN, FANA; Stephen Krieger, MD, FAAN; Clyde E. Markowitz, MD
Release Date: 3/28/2018Expiration Date: 3/27/2019
Credit Type: CMENumber of Credits: 1
Content Type: VideoProvider: Vindico Medical Education
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disorder of the central nervous system that represents the most common cause of nontraumatic neurological disability in young adults. Approximately 10% to 15% of patients with MS have primary progressive MS (PPMS), which, from onset, involves unremitting disease progression, without distinct relapses. Advances in the understanding of the pathogenesis of PPMS have resulted in the development of improved therapeutic approaches. In 2017, ocrelizumab became the first therapy to receive US Food and Drug Administration approval for the treatment of PPMS. Ocrelizumab’s status as the first drug approved for PPMS heralds a radical shift in the treatment paradigm for this disease. Rather than just managing symptoms, physicians now can modify the progressive course of the disease in many patients. In this CME activity, experts will evaluate recent evidence of the contribution of B cells to the pathogenesis of PPMS, as well as discuss how to incorporate new clinical data about B-cell–depleting therapies for the treatment of patients with PPMS into clinical practice.